The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Celldex Therapeutics Inc (NASDAQ: CLDX) closed at $25.5 in the last session, up 2.25% from day before closing price of $24.94. In other words, the price has increased by $2.25 from its previous closing price. On the day, 1.4 million shares were traded. CLDX stock price reached its highest trading level at $25.645 during the session, while it also had its lowest trading level at $24.66.
Ratios:
We take a closer look at CLDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.67 and its Current Ratio is at 19.67. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $64.
On March 20, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $46.
On February 13, 2025, UBS started tracking the stock assigning a Buy rating and target price of $44.UBS initiated its Buy rating on February 13, 2025, with a $44 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when Jimenez Freddy A. sold 771 shares for $24.77 per share. The transaction valued at 19,096 led to the insider holds 34,962 shares of the business.
Marucci Anthony S bought 11,500 shares of CLDX for $308,430 on Nov 11 ’24. The PRESIDENT & CEO now owns 40,284 shares after completing the transaction at $26.82 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1693365760 and an Enterprise Value of 1066060864. For the stock, the TTM Price-to-Sale (P/S) ratio is 292.46 while its Price-to-Book (P/B) ratio in mrq is 2.58. Its current Enterprise Value per Revenue stands at 184.121 whereas that against EBITDA is -4.607.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.20, which has changed by -0.28128523 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $47.00, while it has fallen to a 52-week low of $14.40. The 50-Day Moving Average of the stock is 16.53%, while the 200-Day Moving Average is calculated to be 14.22%.
Shares Statistics:
According to the various share statistics, CLDX traded on average about 1.08M shares per day over the past 3-months and 1230930 shares per day over the past 10 days. A total of 66.39M shares are outstanding, with a floating share count of 64.52M. Insiders hold about 2.84% of the company’s shares, while institutions hold 108.83% stake in the company. Shares short for CLDX as of 1753920000 were 7781241 with a Short Ratio of 7.18, compared to 1751241600 on 7873818. Therefore, it implies a Short% of Shares Outstanding of 7781241 and a Short% of Float of 13.850000000000001.
Earnings Estimates
The market rating of Celldex Therapeutics Inc (CLDX) is currently shaped by the ongoing analysis conducted by 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.92, with high estimates of -$0.82 and low estimates of -$1.02.
Analysts are recommending an EPS of between -$3.07 and -$3.65 for the fiscal current year, implying an average EPS of -$3.41. EPS for the following year is -$4.26, with 9.0 analysts recommending between -$3.68 and -$4.79.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for CLDX’s current fiscal year. The highest revenue estimate was $7.4M, while the lowest revenue estimate was $1.4M, resulting in an average revenue estimate of $3.86M. In the same quarter a year ago, actual revenue was $7.02M
